The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

(January 2022)

T. H. Karlsen, N. Sheron, S. Zelber-Sagi, P. Carrieri, G. Dusheiko, E. Bugianesi, R. Pryke, S. J. Hutchinson, B. Sangro, N. K. Martin, M. Cecchini, M. A. Dirac, A. Belloni, M. Serra-Burriel, C. Y. Ponsioen, B. Sheena, A. Lerouge, M. Devaux, N. Scott, M. Hellard, H. J. Verkade, E. Sturm, G. Marchesini, H. Yki-Järvinen, C. D. Byrne, G. Targher, A. Tur-Sinai, Damon Barrett, et al The Lancet – 2022-01-01, Vol 399, Issue 10319, P61-116

Liver diseases have become a major health threat across Europe, and the face of European hepatology is changing due to the cure of viral hepatitis C and the control of chronic viral hepatitis B, the increasingly widespread unhealthy use of alcohol, the epidemic of obesity, and undiagnosed or untreated liver disease in migrant populations. Consequently, Europe is facing a looming syndemic, in which socioeconomic and health inequities combine to adversely affect liver disease prevalence, outcomes, and opportunities to receive care. In addition, the COVID-19 pandemic has magnified pre-existing challenges to uniform implementation of policies and equity of access to care in Europe, arising from national borders and the cultural and historical heterogeneity of European societies. Read more